Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2010 Earnings Results

Alnylam Pharmaceuticals Misses on EPS — Stock Down 0.92%

Alnylam Pharmaceuticals reported a larger-than-expected loss per share, which contributed to a slight decline in their stock price by 0.92%. Investors may be concerned about the lack of revenue details and the absence of guidance, indicating uncertainty about the company's near-term performance. The defensive tone from management suggests they are aware of the challenges ahead but remain focused on long-term goals.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.35	N/A	-16.67%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management acknowledged the difficulties faced this quarter and reiterated their commitment to long-term growth. They did not provide specific guidance for future performance.

Management highlighted ongoing challenges in achieving profitability.

They emphasized the need for continued investment in R&D despite the losses.

Alnylam Pharmaceuticals Misses on EPS — Stock Down 0.92%

Key numbers

Management commentary

Alnylam Pharmaceuticals, Inc.

More earnings this week

Alnylam Pharmaceuticals Misses on EPS — Stock Down 0.92%

Key numbers

Management commentary